Gregory Abel, MD, MPH, MFA

Gregory Abel, M.D.

617-724-5700

Gregory Abel, MD, MPH, MFA is an outcomes researcher and hematologic oncologist at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School. He helps run DFCI’s Older Adult Hematologic Malignancy (OHM) geriatric hematology research program, serves as Co-Chair of the DFCI Ethics Advisory Committee, and directs DFCI’s Clinical Ethics Service. The Abel research lab applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve their care. Dr. Abel is also interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through his work and collaboration with researchers in oncology, hematology, geriatrics, bioethics, and energy balance, he aims to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life.

Publications View
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia.
Authors: Authors: Hantel A, Cernik C, Uno H, Walsh TP, Calip GS, DeAngelo DJ, Lathan CS, Abel GA.
Blood Cancer J
View full abstract on Pubmed
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Authors: Authors: Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, Hamadani M, Hunink MGM, Cutler C.
Ann Intern Med
View full abstract on Pubmed
Digital Health to Patient-Facing Artificial Intelligence: Ethical Implications and Threats to Dignity for Patients With Cancer.
Authors: Authors: Kelkar AH, Hantel A, Koranteng E, Cutler CS, Hammer MJ, Abel GA.
JCO Oncol Pract
View full abstract on Pubmed
Marital status, frailty, and survival in older adults with blood cancer.
Authors: Authors: Avila J, DuMontier C, Cernik C, Uno H, Hshieh T, Ho K, Mozessohn L, Driver JA, Abel GA.
J Geriatr Oncol
View full abstract on Pubmed
More intensive therapy has a better effect for frail parents with multiple myeloma.
Authors: Authors: DuMontier C, La J, Bihn J, Corrigan J, Yildirim C, Dharne M, Hassan H, Yellapragada S, Abel GA, Gaziano JM, Do NV, Brophy M, Kim DH, Munshi NC, Fillmore NR, Driver JA.
Blood Adv
View full abstract on Pubmed
Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study.
Authors: Authors: Gong IY, Cheung MC, Chan KKW, Arya S, Faught N, Calzavara A, Liu N, Odejide OO, Abel G, Kurdyak P, Raphael MJ, Kuczmarski T, Prica A, Mozessohn L.
J Natl Cancer Inst
View full abstract on Pubmed
Perspectives on Transfusions for Hospice Patients With Blood Cancers: A Survey of Hospice Providers.
Authors: Authors: Knight HP, Brennan C, Hurley SL, Tidswell AJ, Aldridge MD, Johnson KS, Banach E, Tulsky JA, Abel GA, Odejide OO.
J Pain Symptom Manage
View full abstract on Pubmed
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.
Authors: Authors: Hantel A, Luskin MR, Khan I, Warner E, Patel AA, Walsh TP, DeAngelo DJ, Lathan CS, Abel GA.
Haematologica
View full abstract on Pubmed
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
Authors: Authors: Abel GA, Hebert D, Lee C, Rollison D, Gillis N, Komrokji R, Foran JM, Liu JJ, Al Baghdadi T, Deeg J, Gore S, Saber W, Wilson S, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA.
Blood Adv
View full abstract on Pubmed
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
Authors: Authors: DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ.
Blood Adv
View full abstract on Pubmed